Cargando…
Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic malignancy worldwide. However, currently available systemic therapies are of limited effectiveness, and the median overall survival of patients treated with first-line standard chemotherapy is less than one...
Autores principales: | He, Meng-Ye, Yan, Fei-Fei, Cen, Kai-Li, Shen, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669850/ https://www.ncbi.nlm.nih.gov/pubmed/36405269 http://dx.doi.org/10.12998/wjcc.v10.i32.11889 |
Ejemplares similares
-
Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
por: Li, Xiaocheng, et al.
Publicado: (2022) -
Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
por: Zhang, Yu-Qing, et al.
Publicado: (2023) -
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021) -
Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
por: Xie, Peiyi, et al.
Publicado: (2022) -
Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)